Get the app today! App Store Play Store

Nestlé Pays $2bn To Secure Aimmune's Allergy Treatment

Published on Aug 31 2020 9:34 AM

Nestlé Pays $2bn To Secure Aimmune's Allergy Treatment

Nestlé plans to pay $2 billion (€1.7 billion) to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss company expands its fast-growing health science business.

Known for its KitKat chocolate bars and Nescafe instant coffee, Nestlé set up Nestlé Health Science (NHS) in 2011 to open up a new area of business between food and pharma.

Nestlé said in a statement that its offer for Aimmune values the California-based biopharmaceutical firm, which it has been working with since 2016 and in which it already has a stake of around 25.6%, at $2.6 billion (€2.2 billion).

"Aimmune has $261 million in cash and $134 million (€112.7 million) in debt. With our prior investment of $473 million (€397.7 million) in Aimmune, we'll be making a cash payment of just under $2 billion (€1.7 billion)," NHS head Greg Behar told Reuters in an interview.

Food Allergies

Nestlé estimates that up to 240 million people worldwide suffer from food allergies, with peanut allergy being the most common, and with Aimmune, NHS will have prevention, diagnostic and medical treatment options available, Behar said.

Aimmune's Palforzia peanut allergy treatment, which recently gained US approval for children, has sales potential of $1 billion (€840 million), Behar said. The deal is expected to add to organic growth in 2021 and to cash earnings by 2022/23.

The NHS business was on track to more than double sales by 2022, from CHF2 billion (€1.86 billion) in 2014, and was expected to close 2020 at CHF3.3 billion (€3.07 billion), he added.

Global Rollout

"(Palforzia) has 12 years of exclusivity, global rollout will follow and they have the technology platform for other food allergies in development," Behar said.

Nestlé, whose shares were up 0.6% at 07:39 GMT, is offering a 174% premium to Aimmune's closing share price of $12.60 on 28 August.

Aimmune shares hit a record high in January when Palforzia was approved, then dropped during the coronavirus crisis.

Vontobel analyst Jean-Philippe Bertschy said the deal was "another milestone" for NHS after it bought Atrium in 2017.

Nestlé has a market capitalisation of just under CHF317 billion (€294.70 billion), Refinitiv data showed.

News by Reuters edited by Donna Ahern, Checkout. Click subscribe to sign up for the Checkout print edition.

Share on Facebook Share on Twitter Share on LinkedIn Share via Email